CABIO(SH:688089)2022-10-24 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥102,096,355.32, representing a year-on-year increase of 17.62%[5] - The net profit attributable to shareholders for the same period was ¥27,841,760.00, showing a decline of 16.60% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 reached ¥273,244,476.30, an increase of 9.3% compared to ¥249,908,128.65 in the same period of 2021[22] - Net profit for the first three quarters of 2022 was ¥75,304,227.69, a decrease of 27.8% from ¥104,179,165.99 in the same period of 2021[23] - Basic earnings per share for the third quarter of 2022 were ¥0.65, down from ¥0.84 in the same quarter of 2021[24] - The total profit for the first three quarters of 2022 was ¥86,642,442.11, down 10.7% from ¥97,107,838.54 in the same period of 2021[32] Research and Development - The R&D expenses for Q3 2022 totaled ¥11,663,668.37, which is an increase of 99.55% year-on-year, reflecting the company's commitment to expanding its R&D efforts[11] - The proportion of R&D expenses to operating revenue increased to 11.42%, up by 4.69 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2022 were ¥26,333,080.29, compared to ¥17,352,441.12 in the same period of 2021, reflecting a significant investment in innovation[22] - Research and development expenses increased to ¥23,355,921.81, up 53.0% from ¥15,279,592.55 in the previous year[32] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥83,502,609.85, marking an increase of 56.45% compared to the same period last year[6] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 83,502,609.85, an increase of 56.4% compared to CNY 53,374,936.52 in the same period of 2021[25] - The company's cash and cash equivalents decreased to CNY 386,592,981.73 from CNY 664,467,646.87, representing a decline of about 42%[17] - The company's cash and cash equivalents at the end of the period were CNY 382,905,701.10, slightly up from CNY 364,748,739.86 at the end of the previous year[26] - The cash flow from financing activities resulted in a net outflow of -CNY 6,704,513.99, an improvement from -CNY 39,600,000.00 in the same period last year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,541,758,615.76, representing a growth of 6.44% from the end of the previous year[6] - The equity attributable to shareholders at the end of the reporting period was ¥1,428,729,447.17, an increase of 3.45% compared to the previous year[6] - Total liabilities as of the end of the third quarter of 2022 amounted to ¥111,224,600.46, compared to ¥66,677,032.94 at the end of the same period in 2021[20] - The total liabilities increased to CNY 165,419,076.55 from CNY 119,249,041.44, representing a rise of 38.7%[30] - The company's total equity as of September 30, 2022, was CNY 1,425,025,639.81, an increase from CNY 1,379,574,266.50 at the end of 2021, showing a growth of 3.3%[30] Shareholder Information - The company reported a total of 5,570 common shareholders at the end of the reporting period[13] - The company reported a total of 53,100,000 shares held by Wuhan Xiwang Biological Engineering Co., accounting for 44.25% of total shares[14] Investment Activities - Total cash inflow from investment activities was CNY 593,707,456.91, up from CNY 297,485,123.75 in the previous year, indicating a significant increase of 99.7%[26] - The net cash flow from investment activities was -CNY 357,604,092.53, an improvement from -CNY 493,450,082.63 in the same period last year[26] - The company reported a net cash outflow from investing activities of ¥363,550,227.99, an improvement from a net outflow of ¥497,072,258.59 in the previous year[36] Operational Costs - Total operating costs for the first three quarters of 2022 were ¥210,886,748.75, up 31.1% from ¥160,807,974.69 in the previous year[22] - The company reported a total of CNY 147,348,154.50 in cash paid for goods and services, which is an increase of 44.8% compared to CNY 101,668,089.28 in the previous year[25]